icon-    folder.gif   Conference Reports for NATAP  
 
  Back grey_arrow_rt.gif
 
 
 
 
 
FEASIBILITY OF IMPLEMENTING LONG-ACTING INJECTABLE ANTI-RETROVIRAL THERAPY TO TREAT HIV: A SURVEY OF HEALTH PROVIDERS FROM THE 13 COUNTRIES PARTICIPATING IN THE ATLAS-2M TRIAL
 
 
  IAC 2020 July 6-10 Virtual
Reported by Jules Levin
 
IAC 2020 Virtual: Perceived Implementation Barriers Decrease During Initial Stages of an Implementation Science Hybrid III Study (CUSTOMIZE) of Cabotegravir and Rilpivirine Long-Acting (CAB + RPV LA) in US Healthcare Settings: Healthcare Team Perspective - (07/10/20)
 
Deanna Kerrigan,1 Miranda Murray,2 Tahilin Sanchez Karver,3 Andrea Mantsios,4 Nicki
Walters,5 Krischan Hudson,6 Emma Kaplan-Lewis,7 Federico Pulido,8 AC Bassa,9 David Margolis,6 Noya Galai3

1George Washington University, Washington DC, USA; 2Health Analytics & Outcomes, London, UK; 3Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; 4Public Health Innovation & Action, New York, NY, USA; 
5ViiV Healthcare, London, UK; 6ViiV Healthcare, Research Triangle Park, NC, USA; 7Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA; 8HIV Unit, 
Hospital 12 de Octubre, imas12, UCM, Madrid, Spain; 9Mzansi Ethical Research Centre, Middelburg, South Africa

0713201

0713202

0713203

0713204

0713205

0713206